Ligand-Independent Inhibitory Peptides (SCHOOL Peptides) in Medicine
Alexander Sigalov
President, SignaBlok, Inc.
New model of cell signaling, the Signaling Chain HOmoOLigomerization (SCHOOL) model, and synthetic peptides that employ novel, ligand-independent mechanisms of receptor inhibition (SCHOOL peptides) will be briefly reviewed.
Nature-inspired lipopeptide nanoparticles for targeted delivery of SCHOOL peptides and other drugs/imaging agents to macrophages will be also described.
As an exemplary use case, preclinical studies of the SCHOOL peptide inhibitor of TREM-1 receptor in free and nanoparticle-bound forms in cells and animal models of cancer, rheumatoid arthritis, and sepsis will be presented.